0001343009 false 0001343009 2023-01-31 2023-01-31 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): January 31, 2023

 

CNBX PHARMACEUTICALS INC.

(Exact name of registrant as specified in its charter)

 

 

Nevada 000-52403 20-3373669
(State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.)

 

 

#3 Bethesda Metro Center

Suite 700

Bethesda, MD 20814

(Address of principal executive offices and Zip Code)

 

877 424-2429

(Registrant's telephone number, including area code)

 

______________________________

(Former name or former address, if changed since last report.)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions:

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

Title of each class Trading Symbol(s) Name of each exchange on which registered
N/A N/A N/A

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company   ☐ 

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

 

 

   

 

 

ITEM 5.02 – DEPARTURE OF DIRECTORS OR PRINCIPAL OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF PRINCIPAL OFFICERS.

 

On January 31st, 2023, Dr. Inbar Maymon Pomeranchik resigned from her position as a Director and Board Member. Her resignation was not the result of any disagreements with management.

 

Also on January 31st, 2023, Gil Feiler also presented his resignation as a Director and Board Member. His resignation was not the result of any disagreements with management.

 

 

 

 

 

SIGNATURE

 

Pursuant to the requirement of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

 

  CNBX PHARMACEUTICALS INC.
   
   
Date:  February 8, 2023 By: /s/ Eyal Barad
  Eyal Barad
  Chief Executive Officer

 

 

 

 

 2 

 

CNBX Pharmaceuticals (PK) (USOTC:CNBX)
Historical Stock Chart
From Nov 2024 to Dec 2024 Click Here for more CNBX Pharmaceuticals (PK) Charts.
CNBX Pharmaceuticals (PK) (USOTC:CNBX)
Historical Stock Chart
From Dec 2023 to Dec 2024 Click Here for more CNBX Pharmaceuticals (PK) Charts.